|
Mechanism30S subunit inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
100 Clinical Results associated with Respirion Pharmaceuticals Pty Ltd.
0 Patents (Medical) associated with Respirion Pharmaceuticals Pty Ltd.
100 Deals associated with Respirion Pharmaceuticals Pty Ltd.
100 Translational Medicine associated with Respirion Pharmaceuticals Pty Ltd.